Drug Type Radiolabeled antibody |
Synonyms |
Target |
Mechanism HNRNPA2B1 inhibitors(heterogeneous nuclear ribonucleoprotein A2/B1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Triple Negative Breast Cancer | Preclinical | KR | 12 Aug 2022 |